TRCT
CVKD icon

Tower Research Capital (TRC)’s Cadrenal Therapeutics CVKD Stock Holding History

Tower Research Capital (TRC)’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.28K Buy
1,282
+889
+226% +$4.22K ﹤0.01% 4407
2026
Q1 		$2.01K Sell
393
-139
-26% -$974 ﹤0.01% 4560
2025
Q4 		$3.61K Buy
+532
New +$6.01K ﹤0.01% 4341
2025
Q3 		– Sell
-136
Closed -$1.64K – 5282
2025
Q2 		$1.64K Buy
+136
New +$2.02K ﹤0.01% 4769
2025
Q1 		– Sell
-368
Closed -$5.33K – 5287
2024
Q4 		$5.33K Buy
+368
New +$5.32K ﹤0.01% 4307
2024
Q3 		– Sell
-644
Closed -$4.54K – 5743
2024
Q2 		$4.54K Buy
644
+9
+1% +$62 ﹤0.01% 4770
2024
Q1 		$5.81K Buy
635
+69
+12% +$876 ﹤0.01% 4485
2023
Q4 		$6.29K Buy
566
+1
+0.2% +$8 ﹤0.01% 4762
2023
Q3 		$5.76K Buy
565
+547
+3,039% +$7.77K ﹤0.01% 4691
2023
Q2 		$408 Sell
18
-22
-55% -$484 ﹤0.01% 5655
2023
Q1 		$1K Buy
+40
New +$1.22K ﹤0.01% 5515

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
Q1WB
Quest 10 Wealth Builders Fuquay-Varina, Virginia $129M AUM 22.73% 1-Year Est. Return

Tower Research Capital (TRC)'s CVKD Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Cadrenal Therapeutics (CVKD) stake by 226% in Q2 2026, buying an estimated $4.22K and bringing the position to 1,282 shares worth $4.28K. The position accounts for ﹤0.01% of the portfolio, ranked #4407.

Tower Research Capital (TRC) first reported a position in CVKD in Q1 2023 and has held it in 11 quarters since. The position peaked at $6.29K in Q4 2023. 20 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • Tower Research Capital (TRC) held 1,282 shares of Cadrenal Therapeutics worth $4.28K as of Q2 2026.
  • Tower Research Capital (TRC) bought 889 Cadrenal Therapeutics shares in Q2 2026, an estimated $4.22K.
  • Cadrenal Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4407 holding.
  • Tower Research Capital (TRC) first reported a position in Cadrenal Therapeutics in Q1 2023 and has held it in 11 quarters since.
  • Tower Research Capital (TRC)'s Cadrenal Therapeutics position peaked at $6.29K in Q4 2023.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.